| abstract |
The present invention shows that miR-185-5p has higher relative expression levels (2<sup>-ΔCt</sup>; where ΔCt = Ct of the miRNA of interest (miR-185-5p) - Ct of the endogenous miRNA) in patients with asthma compared with healthy individuals. Furthermore, not only are the expression levels of miR-185-5p different between healthy individuals and individuals with asthma, but also between healthy individuals and each of the subgroups of individuals with (intermittent, mild persistent, moderate, and severe) asthma. The results furthermore show that the last two stages of severity, i.e., the moderate and severe persistent stages, show a progressive increase or escalation of the expression thereof compared with mild intermittent and persistent stages. |